Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Cyclacel Pharmaceuticals, Inc. (CYCC : NSDQ)
 
 • Company Description   
CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.

Number of Employees: 6

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.36 Daily Weekly Monthly
20 Day Moving Average: 471,536 shares
Shares Outstanding: 1.58 (millions)
Market Capitalization: $5.32 (millions)
Beta: 0.03
52 Week High: $477.60
52 Week Low: $3.08
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -19.61% -22.03%
12 Week -93.89% -94.71%
Year To Date -96.28% -96.48%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
LEVEL 10 TOWER 11 AVENUE 5 NO. 8 JALAN KERINCHI
-
KUALA LUMPUR,N8 592000
-
ph: 908-517-7330
fax: 866-271-3466
ir@cyclacel.com http://www.cyclacel.com
 
 • General Corporate Information   
Officers
Doris Wong Sing Ee - Chief Executive Officer
Kiu Cu Seng - Chief Financial Officer and Secretary
Avraham Ben-Tzvi - Director
Kwang Fock Chong - Director
David Natan - Director

Peer Information
Cyclacel Pharmaceuticals, Inc. (CORR.)
Cyclacel Pharmaceuticals, Inc. (RSPI)
Cyclacel Pharmaceuticals, Inc. (CGXP)
Cyclacel Pharmaceuticals, Inc. (BGEN)
Cyclacel Pharmaceuticals, Inc. (GTBP)
Cyclacel Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 23254L876
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/24
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 1.58
Most Recent Split Date: 7.00 (0.07:1)
Beta: 0.03
Market Capitalization: $5.32 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.13
Price/Cash Flow: -
Price / Sales: 71.96
EPS Growth
vs. Year Ago Period: 94.70%
vs. Previous Quarter: -83.33%
Sales Growth
vs. Year Ago Period: -37.50%
vs. Previous Quarter: 150.00%
ROE
06/30/25 - -
03/31/25 - -3,648.09
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -155.99
12/31/24 - -188.17
Current Ratio
06/30/25 - -
03/31/25 - 5.60
12/31/24 - 0.59
Quick Ratio
06/30/25 - -
03/31/25 - 5.60
12/31/24 - 0.59
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -55,535.71
12/31/24 - -27,893.02
Book Value
06/30/25 - -
03/31/25 - 2.98
12/31/24 - -58.87
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - -
 

Powered by Zacks Investment Research ©